论文信息 - BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. - 字舞流文

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

H. Zhang | Yi-long Wu | B. Han | Jianxing He | G. Jiang | H. Pan | Xiaoqing Liu | Jie Wang | Caicun Zhou | Gong-yan Chen | Jifeng Feng | Shun Lu | Chunhong Hu | You Lu | G. Cheng | Yunzhong Zhu | Xia Song | A. Yin | S. Lu | W. Zheng | Gongyan Chen